Comparing Machine Learning Models for Aromatase (P450 19A1).

Journal: Environmental science & technology
PMID:

Abstract

Aromatase, or cytochrome P450 19A1, catalyzes the aromatization of androgens to estrogens within the body. Changes in the activity of this enzyme can produce hormonal imbalances that can be detrimental to sexual and skeletal development. Inhibition of this enzyme can occur with drugs and natural products as well as environmental chemicals. Therefore, predicting potential endocrine disruption via exogenous chemicals requires that aromatase inhibition be considered in addition to androgen and estrogen pathway interference. Bayesian machine learning methods can be used for prospective prediction from the molecular structure without the need for experimental data. Herein, the generation and evaluation of multiple machine learning models utilizing different sources of aromatase inhibition data are described. These models are applied to two test sets for external validation with molecules relevant to drug discovery from the public domain. In addition, the performance of multiple machine learning algorithms was evaluated by comparing internal five-fold cross-validation statistics of the training data. These methods to predict aromatase inhibition from molecular structure, when used in concert with estrogen and androgen machine learning models, allow for a more holistic assessment of endocrine-disrupting potential of chemicals with limited empirical data and enable the reduction of the use of hazardous substances.

Authors

  • Kimberley M Zorn
    Collaborations Pharmaceuticals, Inc. , 840 Main Campus Drive, Lab 3510 , Raleigh , North Carolina 27606 , United States.
  • Daniel H Foil
    Department of Chemistry and Biochemistry , University of North Carolina at Greensboro , Greensboro , NC 27402 , USA.
  • Thomas R Lane
    Collaborations Pharmaceuticals, Inc. , Main Campus Drive, Lab 3510 , Raleigh , North Carolina 27606 , United States.
  • Wendy Hillwalker
    Global Product Safety, SC Johnson and Son, Inc., Racine, Wisconsin 53404, United States.
  • David J Feifarek
    Global Product Safety, SC Johnson and Son, Inc., Racine, Wisconsin 53404, United States.
  • Frank Jones
    Global Product Safety, SC Johnson and Son, Inc., Racine, Wisconsin 53404, United States.
  • William D Klaren
    Global Product Safety, SC Johnson and Son, Inc., Racine, Wisconsin 53404, United States.
  • Ashley M Brinkman
    Global Product Safety, SC Johnson and Son, Inc., Racine, Wisconsin 53404, United States.
  • Sean Ekins
    Collaborations in Chemistry, 5616 Hilltop Needmore Road, Fuquay-Varina, NC 27526, USA; Collaborative Drug Discovery, 1633 Bayshore Highway, Suite 342, Burlingame, CA 94010, USA; Collaborations Pharmaceuticals, Inc., 5616 Hilltop Needmore Road, Fuquay-Varina, NC 27526, USA; Phoenix Nest, Inc., P.O. Box 150057, Brooklyn, NY 11215, USA; Hereditary Neuropathy Foundation, 401 Park Avenue South, 10th Floor, New York, NY 10016, USA. Electronic address: ekinssean@yahoo.com.